Use of letermovir for salvage therapy for resistant cytomegalovirus in a pediatric hematopoietic stem cell transplant recipient

Jacob T. Kilgore; Bradford Becken; Matthew G. Varga; Suhag Parikh; Vinod Prasad; Debra Lugo; Yeh Chung Chang

doi:10.1093/JPIDS/PIZ050

Use of letermovir for salvage therapy for resistant cytomegalovirus in a pediatric hematopoietic stem cell transplant recipient

Jacob T. Kilgore, Bradford Becken, Matthew G. Varga, Suhag Parikh, Vinod Prasad, Debra Lugo, Yeh Chung Chang

Research output: Contribution to journal › Article › peer-review

28 Scopus citations

Abstract

We present here the first published use of letermovir for the treatment of resistant cytomegalovirus (CMV) in a pediatric patient. A 14-year-old girl underwent a double unrelated umbilical cord blood transplantation to treat her sickle cell disease (hemoglobin SS) and developed ganciclovir-resistant CMV DNAemia with end-organ involvement that was treated successfully with a combination of foscarnet and letermovir. After she was transitioned to letermovir monotherapy for secondary prophylaxis, she developed recurrent DNAemia with laboratory-confirmed ganciclovir, foscarnet, and letermovir resistance.

Original language	English (US)
Pages (from-to)	486-489
Number of pages	4
Journal	Journal of the Pediatric Infectious Diseases Society
Volume	9
Issue number	4
DOIs	https://doi.org/10.1093/JPIDS/PIZ050
State	Published - 2020
Externally published	Yes

Keywords

Antiviral resistance
Cytomegalovirus (CMV)
Hematopoietic stem cell transplant
Letermovir

ASJC Scopus subject areas

General Medicine

Access to Document

10.1093/JPIDS/PIZ050

Cite this

@article{8ffe8fbf71b4425b877366695db97487,

title = "Use of letermovir for salvage therapy for resistant cytomegalovirus in a pediatric hematopoietic stem cell transplant recipient",

abstract = "We present here the first published use of letermovir for the treatment of resistant cytomegalovirus (CMV) in a pediatric patient. A 14-year-old girl underwent a double unrelated umbilical cord blood transplantation to treat her sickle cell disease (hemoglobin SS) and developed ganciclovir-resistant CMV DNAemia with end-organ involvement that was treated successfully with a combination of foscarnet and letermovir. After she was transitioned to letermovir monotherapy for secondary prophylaxis, she developed recurrent DNAemia with laboratory-confirmed ganciclovir, foscarnet, and letermovir resistance.",

keywords = "Antiviral resistance, Cytomegalovirus (CMV), Hematopoietic stem cell transplant, Letermovir",

author = "Kilgore, {Jacob T.} and Bradford Becken and Varga, {Matthew G.} and Suhag Parikh and Vinod Prasad and Debra Lugo and Chang, {Yeh Chung}",

year = "2020",

doi = "10.1093/JPIDS/PIZ050",

language = "English (US)",

volume = "9",

pages = "486--489",

journal = "Journal of the Pediatric Infectious Diseases Society",

issn = "2048-7193",

publisher = "Oxford University Press",

number = "4",

}

TY - JOUR

T1 - Use of letermovir for salvage therapy for resistant cytomegalovirus in a pediatric hematopoietic stem cell transplant recipient

AU - Kilgore, Jacob T.

AU - Becken, Bradford

AU - Varga, Matthew G.

AU - Parikh, Suhag

AU - Prasad, Vinod

AU - Lugo, Debra

AU - Chang, Yeh Chung

PY - 2020

Y1 - 2020

N2 - We present here the first published use of letermovir for the treatment of resistant cytomegalovirus (CMV) in a pediatric patient. A 14-year-old girl underwent a double unrelated umbilical cord blood transplantation to treat her sickle cell disease (hemoglobin SS) and developed ganciclovir-resistant CMV DNAemia with end-organ involvement that was treated successfully with a combination of foscarnet and letermovir. After she was transitioned to letermovir monotherapy for secondary prophylaxis, she developed recurrent DNAemia with laboratory-confirmed ganciclovir, foscarnet, and letermovir resistance.

AB - We present here the first published use of letermovir for the treatment of resistant cytomegalovirus (CMV) in a pediatric patient. A 14-year-old girl underwent a double unrelated umbilical cord blood transplantation to treat her sickle cell disease (hemoglobin SS) and developed ganciclovir-resistant CMV DNAemia with end-organ involvement that was treated successfully with a combination of foscarnet and letermovir. After she was transitioned to letermovir monotherapy for secondary prophylaxis, she developed recurrent DNAemia with laboratory-confirmed ganciclovir, foscarnet, and letermovir resistance.

KW - Antiviral resistance

KW - Cytomegalovirus (CMV)

KW - Hematopoietic stem cell transplant

KW - Letermovir

UR - http://www.scopus.com/inward/record.url?scp=85091192153&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85091192153&partnerID=8YFLogxK

U2 - 10.1093/JPIDS/PIZ050

DO - 10.1093/JPIDS/PIZ050

M3 - Article

C2 - 31362308

AN - SCOPUS:85091192153

SN - 2048-7193

VL - 9

SP - 486

EP - 489

JO - Journal of the Pediatric Infectious Diseases Society

JF - Journal of the Pediatric Infectious Diseases Society

IS - 4

ER -

Use of letermovir for salvage therapy for resistant cytomegalovirus in a pediatric hematopoietic stem cell transplant recipient

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this